VANIHealthcare · BiotechnologyVANI Stock Forecast: Vivani Medical, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Vivani Medical, Inc. hold a median 12-month price target of $4 — +200.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
VANI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Vivani Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (74): Smaller than most of the companies we track.
Quality (22): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Vivani Medical, Inc. — and when they’d sell — is the membership.
VANI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VANI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +200.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 June 2026 | Lake Street | Initiates | Buy | $4.00 |
| 31 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Nov 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 5 Dec 2022 | ThinkEquity | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VANI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Vivani Medical, Inc. (VANI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −3.0×
- Price / sales
- —
- Price / book
- 5.7×
- EV / EBITDA
- −4.0×
Cheaper than 87% of US stocks
Cheaper than 18% of US stocks
Cheaper than 77% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −176.4%
- Return on assets
- −44.7%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
VANI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VANI appears on the weeks it earns a place.
Frequently asked questions about VANI stock
What is the VANI stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Vivani Medical, Inc. have a median 12-month price target of $4, with estimates ranging from $3.5 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VANI stock a buy right now?
Of the 3 analysts covering Vivani Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vivani Medical, Inc. 28 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VANI?
As at 1 Aug 2026, Vivani Medical, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (74 of 100).
Will VANI stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +200.8% from the last close, and Ticker Nerd's factor model ranks Vivani Medical, Inc. 28 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VANI stock forecast for 2030?
No analyst covering Vivani Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VANI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $4 over the next 12 months.
How has VANI stock performed over the past year?
Vivani Medical, Inc. returned +0.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Vivani Medical, Inc. do?
Vivani Medical Inc. is a specialized biotechnology and medical device company focused on developing innovative solutions in the healthcare sector.
About Vivani Medical, Inc.
Vivani Medical Inc. is a specialized biotechnology and medical device company focused on developing innovative solutions in the healthcare sector. Their primary focus is on addressing chronic diseases and improving patient outcomes through the integration of advanced technologies in bioelectronics. Vivani Medical is particularly notable for its work in creating cutting-edge, implantable medical devices designed to enhance the quality of life for individuals living with sensory deficits and chronic pain. This company operates at the intersection of bioengineering and healthcare, pioneering efforts in providing long-term therapeutic solutions. With a commitment to improving health outcomes, Vivani Medical's developments have potential implications across various medical fields, including neuroscience and chronic disease management, thus playing a significant role in the evolving landscape of medical technology. Their innovative approach underscores the growing importance of bioelectronic medicine as an emerging field that holds promise for addressing some of the most challenging health issues.
CEO Dr. Adam Mendelsohn Ph.D. · 37 employees · United States · https://www.vivani.com